LHFI | Nanologica

NUMBER OF SHARES AND VOTES IN NANOLOGICA AB (PUBL)

30 April, 2026

The number of registered shares and votes in Nanologica AB has changed during the month of April as a result of registration of issues resolved by the Board of Directors on 30 January 2026 and approved by the subsequent Extraordinary General Meeting on 4 March 2026. All parts of the issues are now registered. This means that the number of shares in Nanologica during April has increased by 208,796,242 shares from 119,973,600 to 328,769,842 shares

ANTAL AKTIER OCH RÖSTER I NANOLOGICA AB (PUBL)

30 April, 2026

Antalet registrerade aktier och röster i Nanologica AB har under april månad ändrats till följd av registrering av emissioner som styrelsen beslutade om den 30 januari 2026 och som godkändes på efterföljande extra bolagsstämma den 4 mars 2026. Samtliga delar av emissionerna är nu registrerade. Det innebär att antalet aktier i Nanologica under april har ökat med 208 796 242 aktier från 119 973 600 till 328 769 842 aktier och att aktiekapitalet har ökat med 10 648 608,342 SEK

ANTAL AKTIER OCH RÖSTER I NANOLOGICA AB (PUBL)

31 March, 2026

Antalet registrerade aktier och röster i Nanologica AB har under mars månad ändrats till följd av de riktade emissioner som styrelsen beslutade om den 30 januari 2026 och som godkändes på efterföljande extra bolagsstämma den 4 mars 2026 (de ”Riktade Emissionerna”). De Riktade Emissionerna omfattade totalt 34 203 780 aktier, varav 31 603 780 aktier har delregistrerats under mars månad. De resterande 2 600 000 aktierna förväntas att registreras i samband bolagets företrädesemission. Det innebär att antalet aktier i Nanologica

NUMBER OF SHARES AND VOTES IN NANOLOGICA AB (PUBL)

31 March, 2026

The number of registered shares and votes in Nanologica AB has changed during the month of March as a result of the directed share issues resolved by the board of directors on 30 January 2026 and approved at the subsequent extraordinary general meeting on 4 March 2026 (the "Directed Issues"). The Directed Issues comprised a total of 34,203,780 shares, of which 31,603,780 shares have been partially registered during the month of March. The remaining 2,600,000

Number of Shares and Votes in Nanologica AB (publ)

30 June, 2025

The number of registered shares and votes in Nanologica AB has changed during the month of June following the registration of exercised warrants of series TO5. In 2024, Nanologica issued a total of 11,044,654 warrants of series TO5 within the framework of a rights issue of units. During the period May 7, 2025 to May 21, 2025, holders of warrants of series TO5 have had the right to subscribe for shares by virtue of warrants.

Antal aktier och röster i Nanologica AB (publ)

30 June, 2025

Antalet registrerade aktier och röster i Nanologica AB har förändrats under juni månad efter registrering av nyttjade teckningsoptioner av serie TO5. Under 2024 emitterade Nanologica totalt 11 044 654 teckningsoptioner av serie TO5 inom ramen för en företrädesemission av units. Under perioden den 7 maj 2025 till och med den 21 maj 2025 hade innehavare av teckningsoptioner av serie TO5 rätt att teckna aktier med stöd av teckningsoptioner. En (1) teckningsoption av serie TO5 gav

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.